Shire PLC (NASDAQ:SHPG) – Investment analysts at Piper Jaffray Companies cut their FY2018 earnings per share (EPS) estimates for Shire in a research note issued on Thursday, November 1st. Piper Jaffray Companies analyst D. Amsellem now forecasts that the biopharmaceutical company will post earnings per share of $15.05 for the year, down from their prior forecast of $15.15. Piper Jaffray Companies also issued estimates for Shire’s Q4 2018 earnings at $3.73 EPS, Q2 2019 earnings at $3.90 EPS, Q3 2019 earnings at $4.00 EPS and FY2019 earnings at $15.70 EPS.
SHPG has been the subject of a number of other reports. Cantor Fitzgerald set a $222.00 target price on Shire and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Royal Bank of Canada set a $188.00 price objective on Shire and gave the company a “buy” rating in a research report on Thursday, July 19th. Sanford C. Bernstein downgraded Shire from an “outperform” rating to a “market perform” rating in a research report on Tuesday, September 4th. ValuEngine upgraded Shire from a “sell” rating to a “hold” rating in a research report on Friday, September 21st. Finally, BidaskClub downgraded Shire from a “hold” rating to a “sell” rating in a research report on Thursday, August 16th. Eight analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $201.11.
SHPG opened at $178.97 on Monday. The company has a market capitalization of $53.58 billion, a price-to-earnings ratio of 11.81, a PEG ratio of 1.57 and a beta of 1.02. The company has a debt-to-equity ratio of 0.36, a current ratio of 0.92 and a quick ratio of 0.51. Shire has a 1-year low of $123.73 and a 1-year high of $182.36.
Shire (NASDAQ:SHPG) last released its earnings results on Thursday, November 1st. The biopharmaceutical company reported $3.64 earnings per share for the quarter, missing analysts’ consensus estimates of $3.65 by ($0.01). The firm had revenue of $3.87 billion during the quarter, compared to analyst estimates of $3.86 billion. Shire had a return on equity of 12.70% and a net margin of 30.63%. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter last year, the company earned $3.81 earnings per share.
Large investors have recently made changes to their positions in the company. Morgan Stanley lifted its position in shares of Shire by 25.7% during the 2nd quarter. Morgan Stanley now owns 426,212 shares of the biopharmaceutical company’s stock valued at $71,946,000 after acquiring an additional 87,126 shares during the last quarter. Omni Partners LLP purchased a new stake in shares of Shire in the second quarter valued at $8,297,000. Canyon Capital Advisors LLC purchased a new stake in shares of Shire in the second quarter valued at $14,686,000. Rehmann Capital Advisory Group lifted its holdings in shares of Shire by 226.9% in the second quarter. Rehmann Capital Advisory Group now owns 680 shares of the biopharmaceutical company’s stock valued at $115,000 after purchasing an additional 472 shares in the last quarter. Finally, GAM Holding AG lifted its holdings in shares of Shire by 2,242.5% in the second quarter. GAM Holding AG now owns 46,850 shares of the biopharmaceutical company’s stock valued at $7,908,000 after purchasing an additional 44,850 shares in the last quarter. Institutional investors own 17.89% of the company’s stock.
Shire Company Profile
Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.
Further Reading: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.